Bicalutamide (Synonyms: 比卡鲁胺)

目录号: HY-14249 纯度: 99.91%: Data Sheet SDS COA 产品使用指南技术支持

溶解度

动物溶解方案

Bicalutamide 是一种具有口服活性的非甾体雄激素受体 (AR) 拮抗剂。Bicalutamide 可用于前列腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bicalutamide Chemical Structure

CAS No. : 90357-06-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
50 mg	￥500	In-stock
100 mg	￥750	In-stock
200 mg	￥1100	In-stock
500 mg	￥2100	In-stock
1 g	￥3300	In-stock
5 g	现货	询价
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Bicalutamide:

MCE 顾客使用本产品发表的 13 篇科研文献

RT-PCR

: Bicalutamide purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 8;7(1):3058. [Abstract]; CXCR7 mRNA in cells treated with 2 µM Bicalutamide (BiC) relative to untreated (UT) cells.

Bicalutamide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer^[1].

IC₅₀ & Target

Androgen receptor^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	200 nM Compound: 3	Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting	[PMID: 20381361]
COS-1	IC₅₀	8.69 x 10^-2 μM Compound: Bic	Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay	[PMID: 25646649]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at androgen receptor expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay Agonist activity at androgen receptor expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22391033]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at androgen receptor T877A mutant expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay Agonist activity at androgen receptor T877A mutant expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	> 10 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at human androgen receptor expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	0.18 μM Compound: Bicalutamide	Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay	[PMID: 23199477]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay	[PMID: 23199477]
CV-1	EC₅₀	> 10000 nM Compound: Bicalutamide	Agonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay Agonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay	[PMID: 18442912]
CV-1	IC₅₀	0.3 μM Compound: Casodex	Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay	[PMID: 20826091]
CV-1	IC₅₀	162 nM Compound: Bicalutamide	Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay	[PMID: 18442912]
CV-1	IC₅₀	162 nM Compound: bicalutamide	Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay	[PMID: 18400499]
CWR22R	GI₅₀	3.81 μM Compound: Casodex	Growth inhibition of human CWR22Rv1 cells by MTT assay Growth inhibition of human CWR22Rv1 cells by MTT assay	[PMID: 25634130]
CWR22R	IC₅₀	4.6 μM Compound: 4	Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay	[PMID: 24900588]
CWR22R	IC₅₀	46.25 μM Compound: Bicalutamide	Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay	[PMID: 26965862]
CWR22R	IC₅₀	48.49 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human 22Rv1 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human 22Rv1 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
CWR22R	IC₅₀	49.577 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
CWR22R	IC₅₀	49.58 μM Compound: RS-Bicalutamide	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
CWR22R	IC₅₀	49.6 μM Compound: 1	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
DU-145	IC₅₀	18 μM Compound: Bicalutamide	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	46.031 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human DU145 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human DU145 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
DU-145	IC₅₀	49.2 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
DU-145	IC₅₀	49.2 μM Compound: RS-Bicalutamide	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
DU-145	IC₅₀	49.2 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
DU-145	IC₅₀	64 μM Compound: Casodex	Cytotoxicity against human androgen-independent DU145 cells by MTT assay Cytotoxicity against human androgen-independent DU145 cells by MTT assay	[PMID: 22326399]
HEK293	IC₅₀	0.054 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs	[PMID: 22391033]
HEK293	IC₅₀	0.054 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs	[PMID: 22094279]
HEK293	IC₅₀	0.12 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor T877A mutant expressed in HEK293 cells after 3 hrs Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor T877A mutant expressed in HEK293 cells after 3 hrs	[PMID: 22391033]
HEK293	IC₅₀	0.12 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs	[PMID: 22094279]
HeLa	IC₅₀	140 nM Compound: 3	Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay	[PMID: 17804229]
HeLa	IC₅₀	140 nM Compound: 3	Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay	[PMID: 17064916]
HeLa	IC₅₀	200 nM Compound: 3	Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay	[PMID: 21050768]
LNCaP	IC₅₀	> 100 μM Compound: Casodex	Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days	[PMID: 23301637]
LNCaP	IC₅₀	0.27 μM Compound: Bicalutamide	Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay	[PMID: 23727044]
LNCaP	IC₅₀	0.94 μM Compound: 4	Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay	[PMID: 24900588]
LNCaP	EC₅₀	1.4 μM Compound: 2	Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis	[PMID: 23713567]
LNCaP	IC₅₀	1.71 μM Compound: Casodex	Cytotoxicity against human androgen-dependent LNCAP cells by MTT assay Cytotoxicity against human androgen-dependent LNCAP cells by MTT assay	[PMID: 22326399]
LNCaP	IC₅₀	2.38 μM Compound: BIC	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 4 days by MTT assay in presence of DHT and E2 Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 4 days by MTT assay in presence of DHT and E2	[PMID: 26780832]
LNCaP	GI₅₀	2.61 μM Compound: Casodex	Growth inhibition of human LNCAP cells by MTT assay Growth inhibition of human LNCAP cells by MTT assay	[PMID: 25634130]
LNCaP	IC₅₀	23.79 μM Compound: Bicalutamide	Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method	[PMID: 23727044]
LNCaP	IC₅₀	400 nM Compound: 5	Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay	[PMID: 20584610]
LNCaP	IC₅₀	45.269 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
LNCaP	IC₅₀	45.27 μM Compound: RS-Bicalutamide	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
LNCaP	IC₅₀	45.3 μM Compound: 1	Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
LNCaP	IC₅₀	47.266 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human LNCAP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human LNCAP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
LNCaP	IC₅₀	550 nM Compound: 3	Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days	[PMID: 20381361]
LNCaP	IC₅₀	600 nM Compound: 3	Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days	[PMID: 21050768]
LNCaP	IC₅₀	732.7 nM Compound: 2	Antiproliferative activity against human LNCAP cells after 3 days Antiproliferative activity against human LNCAP cells after 3 days	[PMID: 26046313]
LNCaP	IC₅₀	74 μM Compound: (R,S)Bicalutamide	Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay	[PMID: 22672984]
MDA-MB-435	IC₅₀	173 nM Compound: 5	Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay	[PMID: 20584610]
PC-3	IC₅₀	> 10 μM Compound: 4	Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by WST-8 assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by WST-8 assay	[PMID: 24900588]
PC-3	IC₅₀	60.69 μM Compound: BIC	Antiproliferative activity against AR negative human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against AR negative human PC3 cells after 48 hrs by MTT assay	[PMID: 28162857]
PC-3	IC₅₀	76.4 μM Compound: (R,S)Bicalutamide	Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay	[PMID: 22672984]
PC-3	IC₅₀	77 μM Compound: Casodex	Cytotoxicity against human androgen-independent PC3 cells by MTT assay Cytotoxicity against human androgen-independent PC3 cells by MTT assay	[PMID: 22326399]
PC-3	GI₅₀	9.15 μM Compound: Casodex	Growth inhibition of human PC3 cells by MTT assay Growth inhibition of human PC3 cells by MTT assay	[PMID: 25634130]
SC-3	IC₅₀	0.67 μM Compound: 1	Antiandrogen activity against androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell proliferation by WST1 assay Antiandrogen activity against androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell proliferation by WST1 assay	[PMID: 20888766]
SC-3	IC₅₀	3 μM Compound: Bicalutamide	Antagonist activity at androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell growth after 3 days Antagonist activity at androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell growth after 3 days	[PMID: 23462715]
VCaP	IC₅₀	64.712 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human VCaP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human VCaP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
VCaP	IC₅₀	68.37 μM Compound: RS-Bicalutamide	Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
VCaP	IC₅₀	68.37 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
VCaP	IC₅₀	68.4 μM Compound: 1	Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]

体外研究
(In Vitro)

在全细胞结合试验 (LNCaP/AR (cs) 细胞) 中，Bicalutamide 与雄激素竞争结合 AR，IC₅₀ 为 160 nM^[1]。
Bicalutamide 以剂量依赖性方式诱导 VCaP 细胞增殖，同时部分拮抗 R1881 (合成雄激素)^[1]的作用。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Bicalutamide (10 mg/kg；ig；每天；持续 28 天) 在前列腺癌小鼠模型中表现出抗肿瘤活性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Castrate male mice, bearing LNCaP/AR(cs) xenograft tumors^[1]
Dosage:	10 mg/kg
Administration:	Oral gavage, daily, for 28 days
Result:	Inhibited tumors growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01786265	M.D. Anderson Cancer Center	Prostate Adenocarcinoma\|Recurrent Prostate Carcinoma	February 5, 2013	Phase 2
NCT03043807	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Prostate Cancer	February 22, 2017	Phase 2
NCT00684905	Mayo Clinic\|National Cancer Institute (NCI)	Prostate Cancer	April 2000	Phase 2
NCT02531516	Aragon Pharmaceuticals, Inc.	Prostatic Neoplasms	November 2015	Phase 3
NCT01039233	Kremers Urban Development Company\|Watson Laboratories, Inc.	Bioequivalency	May 2005	Phase 1
NCT00067015	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Prostate Cancer	May 2003	Phase 3
NCT00099086	Medical University of South Carolina	Prostate Cancer	January 16, 2007	Phase 1
NCT00293696	Tampere University	Prostate Cancer	October 2004	Phase 4
NCT02346253	Stanford University\|National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Stage I Prostate Cancer\|Stage IIA Prostate Cancer\|Stage IIB Prostate Cancer\|Stage III Prostate Cancer	January 13, 2015	Not Applicable
NCT04943536	Alessa Therapeutics Inc.\|National Cancer Institute (NCI)	Prostate Adenocarcinoma	October 1, 2021	Phase 1
NCT02348281	Fudan University	Breast Cancer	January 2015	Phase 2
NCT00884273	Ferring Pharmaceuticals	Prostate Cancer	August 2009	Phase 3
NCT02382094	Karolinska University Hospital	Prostate Cancer	June 2005	Phase 3
NCT02299999	UNICANCER\|Fondation ARC\|AstraZeneca	Metastatic Breast Cancer	April 7, 2014	Phase 2
NCT00030654	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group\|Cancer and Leukemia Group B\|SWOG Cancer Research Network\|NRG Oncology	Prostate Cancer	October 2002	Phase 3
NCT04652765	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Covid19\|SARS-CoV Infection\|Coronavirus Infection	February 3, 2021	Phase 1
NCT00002633	NCIC Clinical Trials Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group\|SWOG Cancer Research Network\|Medical Research Council\|Canadian Cancer Trials Group	Prostate Cancer	February 8, 1995	Phase 3
NCT05979389	University of California, San Francisco\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NAFLD\|PCOS	August 2023	Phase 1
NCT00551044	Wirral University Teaching Hospital NHS Trust\|AstraZeneca	Prostatic Neoplasms	August 2003	Not Applicable
NCT00023829	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NCIC Clinical Trials Group	Prostate Cancer	August 2001	Phase 3
NCT00769795	University of Washington	Prostate Cancer	October 2008	Phase 2
NCT00470834	GlaxoSmithKline	Neoplasms, Prostate	May 2007	Phase 4
NCT04049747	Imperial College London\|Prostate Cancer UK\|Imperial Clinical Trials Unit (ICTU)	Prostate Cancer\|Non-metastatic Prostate Cancer\|Prostate Adenocarcinoma	December 11, 2019	Not Applicable
NCT00630344	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Novartis Pharmaceuticals	Prostate Cancer	February 2008	Phase 2
NCT00586898	Memorial Sloan Kettering Cancer Center	Prostate\|Cancer\|Hormonal Cycling	July 2001	Phase 2
NCT04034095	Janssen Pharmaceutical K.K.	Prostatic Neoplasms	July 8, 2019
NCT03650894	Providence Health & Services\|Bristol-Myers Squibb\|Memorial Sloan Kettering Cancer Center	Breast Neoplasm Female\|Breast Cancer\|Breast Carcinoma\|Breast Tumor	April 3, 2019	Phase 2
NCT02615223	Tianjin Medical University Cancer Institute and Hospital\|Peking University First Hospital\|Tianjin First Central Hospital\|Shandong Cancer Hospital and Institute\|Shanghai Jiao Tong University School of Medicine\|The Third Xiangya Hospital of Central South University\|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Stage IV Prostate Cancer	November 2015	Not Applicable
NCT00170157	Mayo Clinic\|National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Prostate Carcinoma\|Recurrent Prostate Carcinoma\|Stage III Prostate Cancer\|Stage IV Prostate Cancer	June 2004	Phase 2
NCT00026377	University of Chicago\|National Cancer Institute (NCI)	Prostate Cancer	November 2001	Phase 1
NCT04374279	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	COVID-19\|SARS-CoV 2	April 2021	Phase 2
NCT01200810	National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer\|Stage IV Prostate Cancer	August 2010	Phase 2
NCT00094328	AstraZeneca	Puberty, Precocious	November 22, 2004	Phase 2
NCT00512668	National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer	September 2007	Phase 1
NCT00468715	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|AstraZeneca	Breast Cancer	March 23, 2007	Phase 2
NCT01664923	Pfizer\|Astellas Pharma Inc\|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.	Prostate Cancer	August 2012	Phase 2
NCT01020305	Sandy Srinivas\|Wyeth is now a wholly owned subsidiary of Pfizer\|National Comprehensive Cancer Network\|American Society of Clinical Oncology\|Stanford University	Prostate Cancer\|Prostatic Neoplasms\|Castrate-resistant Prostate Cancer (CRPC)\|Androgen-insensitive Prostate Cancer\|Hormone-refractory Prostate Cancer\|Metastatic Disease	October 2009	Phase 1\|Phase 2
NCT02085252	Takeda	Prostate Cancer	June 3, 2013	Phase 3
NCT03055312	Sun Yat-sen University	Metastatic Triple Negative Breast Cancer	December 20, 2016	Phase 3
NCT00658697	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Beth Israel Deaconess Medical Center\|Genentech, Inc.	Prostate Cancer	June 2008	Phase 2
NCT02058706	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer\|Stage IV Prostate Cancer	May 2014	Phase 2
NCT01288911	Astellas Pharma Inc\|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.	Prostatic Neoplasms	March 22, 2011	Phase 2
NCT05095207	Icahn School of Medicine at Mount Sinai	Breast Cancer\|Metastasis	September 29, 2021	Phase 1\|Phase 2
NCT00685633	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Prostate Cancer	December 2008	Phase 2
NCT00814788	University of California, Davis\|Novartis	Prostate Cancer	December 2008	Phase 2
NCT00349557	Benaroya Research Institute\|Genentech, Inc.	Prostate Cancer	April 2006	Phase 2
NCT00255268	AstraZeneca	Metastatic Prostate Cancer	August 2004	Phase 4
NCT01969578	European Organisation for Research and Treatment of Cancer - EORTC	Salivary Gland Cancer	September 24, 2015	Phase 2
NCT00936390	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Prostate Cancer	September 2009	Phase 3
NCT00028769	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Prostate Cancer	December 2001	Phase 2
NCT00771017	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Prostate Cancer	July 2008	Phase 2
NCT00528866	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Prostate Cancer	April 2008	Phase 2
NCT00233610	AstraZeneca	Prostate Cancer	December 2003	Phase 3
NCT04248621	Wonju Severance Christian Hospital\|Eulji University Hospital	Prostatic Neoplasms	January 23, 2020	Phase 4
NCT05019846	Marco Lorenzo Bonu\|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Prostate Cancer	September 30, 2021	Phase 3
NCT02366494	Medical College of Wisconsin	Prostate Cancer	April 29, 2015
NCT03141671	Dana-Farber Cancer Institute\|Janssen Pharmaceutica	Prostate Cancer	November 24, 2017	Phase 2
NCT00486642	National Cancer Institute (NCI)	Hormone-Resistant Prostate Cancer\|Recurrent Prostate Carcinoma	September 2007	Phase 2
NCT00003653	NCIC Clinical Trials Group\|National Cancer Institute (NCI)\|SWOG Cancer Research Network\|Canadian Cancer Trials Group	Prostate Cancer	January 5, 1999	Phase 3
NCT00846976	AstraZeneca	Prostate Cancer	December 1994	Phase 3
NCT00943956	Institut du Cancer de Montpellier - Val d´Aurelle	Prostate Cancer	January 2009	Phase 1
NCT02582749	Ajjai Alva, MD\|Hoosier Cancer Research Network\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma	Prostate Cancer\|Bone Metastases\|Prostate Neoplasms	April 2016	Phase 2
NCT00002874	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|SWOG Cancer Research Network\|NRG Oncology	Prostate Cancer	February 1998	Phase 3
NCT02487823	Institut Paoli-Calmettes\|Novartis	Non Castrate Metastatic Prostate Cancer	October 2014	Phase 1
NCT04734730	City of Hope Medical Center\|National Cancer Institute (NCI)	Castration-Sensitive Prostate Carcinoma\|Metastatic Prostate Adenocarcinoma\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	May 4, 2021	Phase 2
NCT00536653	Wirral University Teaching Hospital NHS Trust	Osteoporosis	October 1999	Not Applicable
NCT01120236	National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Recurrent Prostate Carcinoma\|Stage IV Prostate Cancer	December 2010	Phase 2
NCT05647356	Royal College of Surgeons, Ireland\|University of Birmingham\|University of Liverpool\|University of Oxford\|University College Dublin	Polycystic Ovary Syndrome\|Androgen Excess\|Metabolic Disease	January 1, 2023	Not Applicable
NCT00482807	University of Nebraska\|National Cancer Institute (NCI)	Prostate Cancer	August 2004	Phase 1
NCT03147196	Mayo Clinic\|National Cancer Institute (NCI)	Stage I Prostate Adenocarcinoma\|Stage II Prostate Adenocarcinoma	June 27, 2017	Phase 2
NCT02614859	Fox Chase Cancer Center	Cancer of Prostate	December 1, 2015	Phase 2
NCT04025372	Dana-Farber Cancer Institute\|Bayer\|Decipher Biosciences	Prostate Cancer	June 1, 2020	Phase 2
NCT03358563	University of Wisconsin, Madison\|United States Department of Defense\|Prostate Cancer Foundation	Prostate Cancer	January 17, 2018	Early Phase 1
NCT03678025	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Castration Levels of Testosterone\|Metastatic Prostatic Adenocarcinoma\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	September 24, 2018	Phase 3
NCT00866554	CHU de Quebec-Universite Laval\|GlaxoSmithKline	Prostate Cancer\|Erectile Dysfunction\|Lower Urinary Tract Symptoms	March 2009	Phase 2
NCT00831233	Ferring Pharmaceuticals	Prostate Cancer	April 2009	Phase 3
NCT00003026	European Organisation for Research and Treatment of Cancer - EORTC	Prostate Cancer	April 1997	Phase 3
NCT00328614	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Cytogen Corporation\|Thomas Jefferson University	Prostate Cancer	March 2003	Phase 1
NCT02697032	University Medical Center Groningen	Breast Cancer	February 2016	Phase 2
NCT00244920	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Prostate Cancer	January 2002	Phase 2
NCT01809691	SWOG Cancer Research Network\|Millennium Pharmaceuticals, Inc.\|National Cancer Institute (NCI)	Prostate Cancer	March 8, 2013	Phase 3
NCT05087706	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Salivary Gland Neoplasms	July 30, 2021
NCT02910050	Xu fei\|Sun Yat-sen University	Breast Cancer	January 2016	Phase 2
NCT02059213	University of Michigan Rogel Cancer Center\|University of Utah\|Vanderbilt-Ingram Cancer Center\|Johns Hopkins University\|Thomas Jefferson University\|Washington University School of Medicine\|Northwestern University\|City of Hope Comprehensive Cancer Center	Prostate Cancer	June 2014	Phase 2
NCT00702923	University of Wisconsin, Madison\|Pfizer	Prostate Cancer	July 2008	Phase 1
NCT00960310	Sandoz	Prostate Cancer\|Hirsutism	June 2006	Phase 1
NCT00014586	European Organisation for Research and Treatment of Cancer - EORTC	Prostate Cancer	January 2001	Phase 3
NCT00521781	The Methodist Hospital Research Institute\|Celgene Corporation	Prostatic Neoplasms	August 2007	Phase 2
NCT01251861	National Cancer Institute (NCI)	Recurrent Prostate Carcinoma\|Stage I Prostate Cancer AJCC v7\|Stage IIA Prostate Cancer AJCC v7\|Stage IIB Prostate Cancer AJCC v7\|Stage III Prostate Cancer AJCC v7	December 23, 2010	Phase 2
NCT03520478	Jiangsu HengRui Medicine Co., Ltd.	Prostate Cancer\|Hormone-Dependent Prostate Cancer	May 30, 2018	Phase 3
NCT02353988	Jinling Hospital, China\|Wenzhou Medical University\|The First People´s Hospital of Lianyungang\|Wuxi People´s Hospital\|Nanning Second People´s Hospital\|Jiangsu Province Hospital of Traditional Chinese Medicine\|The Second Hospital of Nanjing Medical University	Breast Neoplasms	January 2015	Phase 2
NCT00002651	SWOG Cancer Research Network\|National Cancer Institute (NCI)\|NCIC Clinical Trials Group\|Cancer and Leukemia Group B\|Eastern Cooperative Oncology Group\|European Organisation for Research and Treatment of Cancer - EORTC	Prostate Cancer	May 1995	Phase 3
NCT00108732	National Cancer Institute (NCI)	Recurrent Prostate Carcinoma\|Stage I Prostate Cancer\|Stage IIA Prostate Cancer\|Stage IIB Prostate Cancer\|Stage III Prostate Cancer	February 2006	Phase 2
NCT00776594	Dana-Farber Cancer Institute\|Genentech, Inc.\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital\|Rutgers Cancer Institute of New Jersey	Prostate Cancer	October 2008	Phase 2
NCT00004124	SWOG Cancer Research Network\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B	Prostate Cancer	October 15, 1999	Phase 3
NCT04787744	VA Office of Research and Development	Prostate Cancer\|Oligometastasis\|Oligorecurrence\|Recurrent Prostate Cancer\|Metastatic Prostate Cancer	July 1, 2021	Phase 2\|Phase 3
NCT03809000	RTOG Foundation, Inc.\|Pfizer\|Astellas Pharma Inc	Prostate Cancer	April 15, 2019	Phase 2
NCT00075192	AstraZeneca	Prostatic Neoplasms	March 2004	Phase 1\|Phase 2
NCT01050842	Mayo Clinic	Prostate Cancer\|Adenocarcinoma of the Prostate\|Hormone-resistant Prostate Cancer\|Stage IV Prostate Cancer	February 2010	Early Phase 1
NCT00757692	British Columbia Cancer Agency\|AstraZeneca	Prostate Cancer	January 2009	Phase 2
NCT03878524	OHSU Knight Cancer Institute\|Oregon Health and Science University	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Anatomic Stage IV Breast Cancer AJCC v8\|Anemia\|Ann Arbor Stage III Hodgkin Lymphoma\|Ann Arbor Stage III Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Hodgkin Lymphoma\|Ann Arbor Stage IV Non-Hodgkin Lymphoma\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Castration-Resistant Prostate Carcinoma\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Hematopoietic and Lymphoid System Neoplasm\|Locally Advanced Pancreatic Adenocarcinoma\|Metastatic Breast Carcinoma\|Metastatic Malignant Solid Neoplasm\|Metastatic Pancreatic Adenocarcinoma\|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Primary Myelofibrosis\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Hematologic Malignancy\|Recurrent Hodgkin Lymphoma\|Recurrent Myelodysplastic Syndrome\|Recurrent Myelodysplastic+Myeloproliferative Neoplasm\|Recurrent Myeloproliferative Neoplasm\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Plasma Cell Myeloma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Hematologic Malignancy\|Refractory Hodgkin Lymphoma\|Refractory Malignant Solid Neoplasm\|Refractory Myelodysplastic Syndrome\|Refractory Myelodysplastic+Myeloproliferative Neoplasm\|Refractory Non-Hodgkin Lymphoma\|Refractory Plasma Cell Myeloma\|Refractory Primary Myelofibrosis\|Refractory Small Lymphocytic Lymphoma\|Stage II Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8\|Stage IV Pancreatic Cancer AJCC v8\|Stage IV Prostate Cancer AJCC v8\|Unresectable Pancreatic Adenocarcinoma	April 1, 2020	Phase 1
NCT01420250	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Sanofi\|Thomas Jefferson University	Prostate Cancer	September 22, 2011	Phase 1
NCT03090165	Kari Wisinski\|Novartis\|Big Ten Cancer Research Consortium\|University of Wisconsin, Madison	Triple Negative Breast Cancer	May 7, 2018	Phase 1\|Phase 2
NCT00636259	AstraZeneca	Adenocarcinoma of the Prostate
NCT05050084	NRG Oncology\|National Cancer Institute (NCI)	Prostate Adenocarcinoma	November 3, 2021	Phase 3
NCT00004054	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)	Prostate Cancer	January 2000	Phase 3
NCT00672282	AstraZeneca\|Scandinavian Prostate Cancer Group	Non-Metastatic Prostate Cancer	October 1995	Phase 3
NCT03541928	The Methodist Hospital Research Institute	High-risk Prostate Cancer\|Prostate Cancer	August 2, 2018	Phase 2
NCT00055731	UNICANCER\|Sanofi\|AstraZeneca	Prostate Cancer	November 14, 2002	Phase 3
NCT02716974	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Prostate Cancer	June 2016	Phase 2
NCT00421694	University of L´Aquila	Prostate Cancer		Phase 2\|Phase 3
NCT03458221	Gynaecologisch Oncologisch Centrum Zuid\|Radboud University Medical Center\|Erasmus Medical Center\|Maastricht University Medical Center\|InnoSIGN\|Eurofins	Recurrent Ovarian Cancer\|Signal Transduction Pathway Deregulation\|Therapy-Associated Cancer	January 31, 2023	Phase 2\|Phase 3
NCT02146937	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Detectable Prostate Nodules	March 2014	Phase 2
NCT00544830	City of Hope Medical Center\|National Cancer Institute (NCI)	PSA Level Greater Than Two\|Stage IV Prostate Adenocarcinoma AJCC v7	July 18, 2006	Phase 2
NCT00972855	Teva Pharmaceuticals USA	Healthy	September 2003	Phase 1
NCT00541047	Medical Research Council\|Canadian Cancer Trials Group	Gastrointestinal Complications\|Prostate Cancer\|Sexual Dysfunction\|Urinary Complications	November 2007	Phase 3
NCT00021450	European Organisation for Research and Treatment of Cancer - EORTC	Prostate Cancer	April 2001	Phase 3
NCT00959335	Sandoz	Prostate Cancer\|Hirsutism	August 2006	Phase 1
NCT00012090	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Fallopian Tube Cancer\|Ovarian Cancer\|Primary Peritoneal Cavity Cancer	September 2000	Phase 2
NCT05513365	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development	Salivary Duct Carcinoma	September 27, 2022	Phase 2
NCT01658527	European Organisation for Research and Treatment of Cancer - EORTC	Prostate Cancer	January 2014	Phase 2
NCT00589472	National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Stage I Prostate Cancer\|Stage IIA Prostate Cancer\|Stage IIB Prostate Cancer\|Stage III Prostate Cancer	November 2007	Phase 2
NCT01342367	University of Chicago	Prostate Cancer	December 17, 2010	Not Applicable
NCT04509999	University of Florida	COVID-19	October 26, 2020	Phase 3
NCT00418080	University of L´Aquila	Prostate Cancer	April 2002	Phase 2
NCT04513717	NRG Oncology\|National Cancer Institute (NCI)	Metastatic Malignant Neoplasm in the Bone\|Prostate Adenocarcinoma\|Stage III Prostate Cancer AJCC v8\|Stage IIIA Prostate Cancer AJCC v8\|Stage IIIB Prostate Cancer AJCC v8\|Stage IIIC Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8	December 15, 2020	Phase 3
NCT00878436	NYU Langone Health\|Novartis	Prostate Cancer\|Prostatic Neoplasms	June 2009	Phase 1\|Phase 2
NCT00651326	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Prostate Cancer	June 2, 2008	Phase 3
NCT03587285	Guangzhou University of Traditional Chinese Medicine\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Prostatic Neoplasms	September 23, 2018	Phase 1\|Phase 2
NCT00086736	University of Alabama at Birmingham\|National Cancer Institute (NCI)	Prostate Cancer	November 2001	Phase 2
NCT00973050	Teva Pharmaceuticals USA	Healthy	September 2003	Phase 1
NCT02605486	Memorial Sloan Kettering Cancer Center\|Pfizer	Metastatic Breast Cancer (MBC)	November 11, 2015	Phase 1\|Phase 2
NCT00666666	National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Stage IV Prostate Cancer	July 2009	Phase 2
NCT00348998	Virginia Mason Hospital+Medical Center\|National Cancer Institute (NCI)	Prostate Cancer	April 2006	Phase 2
NCT00514917	Sanofi	Prostatic Neoplasms	July 2007	Phase 3
NCT00003517	Burzynski Research Institute\|National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Stage III Prostate Cancer\|Stage IV Prostate Cancer\|Recurrent Prostate Cancer		Phase 2
NCT00659438	Genzyme, a Sanofi Company\|Sanofi	Prostate Cancer	February 2008	Phase 2
NCT03070886	NRG Oncology\|National Cancer Institute (NCI)	Stage I Prostate Adenocarcinoma\|Stage II Prostate Adenocarcinoma\|Stage III Prostate Adenocarcinoma	January 16, 2017	Phase 2\|Phase 3
NCT00841113	Speciality European Pharma Limited	Prostate Cancer	January 1999	Phase 3
NCT00388804	M.D. Anderson Cancer Center	Prostate Cancer	February 2005	Phase 3
NCT00833248	Ferring Pharmaceuticals	Prostate Cancer	April 2009	Phase 3
NCT01044706	Kremers Urban Development Company\|Watson Pharmaceuticals	Healthy	May 2005	Phase 1
NCT05327647	CHU de Quebec-Universite Laval\|Canadian Institutes of Health Research (CIHR)	Non-Muscle Invasive Bladder Cancer	June 23, 2022	Phase 2
NCT02605226	Tianjin Medical University Cancer Institute and Hospital\|The Third Xiangya Hospital of Central South University\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|Peking University First Hospital\|Shanghai Jiao Tong University School of Medicine\|Shandong Cancer Hospital and Institute\|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Tianjin First Central Hospital	Stage III Prostate Cancer	November 2015	Not Applicable
NCT00657904	AstraZeneca	Non-metastatic Prostate Cancer	August 1995	Phase 3
NCT00673205	AstraZeneca	Non-Metastatic Prostate Cancer	September 1995	Phase 3
NCT02742675	Fudan University	Prostate Cancer	September 2015	Phase 2
NCT00002855	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Prostate Cancer	August 1996	Phase 3
NCT00298155	University of Washington\|GlaxoSmithKline\|AstraZeneca	Cancer\|Prostate Neoplasms	July 2006	Phase 2
NCT04284761	Alessa Therapeutics Inc.	Prostate Adenocarcinoma\|Lower Urinary Tract Symptoms	October 11, 2020	Phase 1

分子量

430.37

Formula

C₁₈H₁₄F₄N₂O₄S

CAS 号

90357-06-5

性状

固体

颜色

White to off-white

中文名称

比卡鲁胺

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 50 mg/mL (116.18 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3236 mL	11.6179 mL	23.2358 mL
5 mM	0.4647 mL	2.3236 mL	4.6472 mL
10 mM	0.2324 mL	1.1618 mL	2.3236 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

扫码获得
动物溶解方案

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO， PEG300/PEG400，Tween 80，均可在 MCE 网站选购。

纯度 & 产品资料

纯度： 99.91%

选择批次：

Data Sheet (632 KB) SDS (393 KB)

COA (287 KB)LCMS (92 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Nicola J. Clegg,1 John Wongvipat,1,2 Jim Joseph, ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 March 15; 72(6): 1494-1503.

Bicalutamide 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3236 mL	11.6179 mL	23.2358 mL	58.0896 mL
	5 mM	0.4647 mL	2.3236 mL	4.6472 mL	11.6179 mL
	10 mM	0.2324 mL	1.1618 mL	2.3236 mL	5.8090 mL
	15 mM	0.1549 mL	0.7745 mL	1.5491 mL	3.8726 mL
	20 mM	0.1162 mL	0.5809 mL	1.1618 mL	2.9045 mL
	25 mM	0.0929 mL	0.4647 mL	0.9294 mL	2.3236 mL
	30 mM	0.0775 mL	0.3873 mL	0.7745 mL	1.9363 mL
	40 mM	0.0581 mL	0.2904 mL	0.5809 mL	1.4522 mL
	50 mM	0.0465 mL	0.2324 mL	0.4647 mL	1.1618 mL
	60 mM	0.0387 mL	0.1936 mL	0.3873 mL	0.9682 mL
	80 mM	0.0290 mL	0.1452 mL	0.2904 mL	0.7261 mL
	100 mM	0.0232 mL	0.1162 mL	0.2324 mL	0.5809 mL

Keywords:

Bicalutamide90357-06-5比卡鲁胺Androgen ReceptorAutophagynon-steroidalandrogenreceptorprostate cancercastration-resistantprostatecanceranti-androgenInhibitorinhibitorinhibit

您最近查看的产品:

Bicalutamide

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Bicalutamide (Synonyms: 比卡鲁胺)

Customer Review

Other Forms of Bicalutamide:

Bicalutamide 相关抗体

MCE 顾客使用本产品发表的 13 篇科研文献

Bicalutamide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Bicalutamide 相关抗体:

摩尔计算器

稀释计算器

Bicalutamide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z